Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

In vivo SPECT imaging of CNS D-2 dopamine receptors: Initial studies with iodine-123-IBZM in humans

Journal Article · · Journal of Nuclear Medicine; (USA)
OSTI ID:6870183
Iodobenzamide (IBZM) is a D-2 dopamine receptor antagonist. In this paper the results of Phase I clinical studies of iodine-123-({sup 123}I)IBZM in humans are reported. Preliminary imaging studies, both planar and single-photon emission tomography (SPECT), of no-carrier added ({sup 123}I)IBZM in humans show specific localization in the basal ganglia of the brain. At 2 hr after an i.v. injection, the brain uptake was 3.72% of the dose, and at 20 hr later the uptake diminished to 0.7%. Radiation dosimetry calculation indicated that the radiation dose to the brain was minimum, 0.039 rad/mCi, while the large intestine wall received the highest dose, 0.28 mrad/mCi. The radiation dosimetry and pharmacology data suggest that this agent is safe for human use.
OSTI ID:
6870183
Journal Information:
Journal of Nuclear Medicine; (USA), Journal Name: Journal of Nuclear Medicine; (USA) Vol. 31:5; ISSN 0161-5505; ISSN JNMEA
Country of Publication:
United States
Language:
English

Similar Records

In vitro and in vivo evaluation of (/sup 123/I)IBZM: a potential CNS D-2 dopamine receptor imaging agent
Journal Article · Sat Dec 31 23:00:00 EST 1988 · J. Nucl. Med.; (United States) · OSTI ID:6406676

Whole-body biodistribution, radiation absorbed dose and brain SPECT imaging with iodine-123-{beta}-CIT in healthy human subjects
Journal Article · Sun May 01 00:00:00 EDT 1994 · Journal of Nuclear Medicine · OSTI ID:95911

Dosimetry of an iodine-123-labeled tropane to image dopamine transporters
Journal Article · Sun Dec 31 23:00:00 EST 1995 · Journal of Nuclear Medicine · OSTI ID:240984